Hereditary Hemorrhagic Telangiectasia (HHT) Center

The Hereditary Hemorrhagic Telangiectasia (HHT) Center opportunity is a federal cooperative agreement program administered by the Health Resources and Services Administration (HRSA), an agency within the U.S. Department of Health and Human Services. The opportunity is listed under Assistance Listing 93.110, Special Projects of Regional and National Significance, and is identified by opportunity number HRSA-26-092. This program is intended to support a national clinical center focused on improving care, diagnosis, and data coordination related to Hereditary Hemorrhagic Telangiectasia, a rare genetic disorder that can lead to severe bleeding complications, organ malformations, and increased risk of illness and death. HRSA anticipates making one award under this opportunity and has forecasted total program funding of $2,900,000. The purpose of the HHT Center Program is to reduce illness and mortality associated with hereditary hemorrhagic telangiectasia by strengthening access to coordinated specialty care, improving provider identification and diagnosis of HHT cases, and building infrastructure to support improved understanding of treatment outcomes. The program description specifically emphasizes partnership with a clinical center capable of expanding care coordination activities and creating innovative diagnostic support strategies for clinicians. Another central objective is the development of a de-identified aggregate patient data registry that can support future research, patient tracking, and evidence-based improvements in clinical management of this rare disease population. The funding opportunity is categorized under the Health funding activity category and will be administered as a cooperative agreement, indicating substantial federal involvement in the funded activities. The estimated award ceiling and total available funding are both listed as $2,900,000, suggesting that HRSA expects to issue a single award covering the full program allocation. No cost sharing or matching requirement is identified in the forecast notice. The estimated project start date is September 1, 2026, following an estimated award date of August 2, 2026. While the forecast announcement does not specify the project period length, the anticipated award structure suggests support for a centralized national program focused on clinical coordination and patient registry development. Eligibility for the program is broad and includes unrestricted applicants as well as state governments, subject to any clarifications contained within future application materials. The notice defines “domestic” eligibility to include the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. Because the forecast announcement references unrestricted eligibility, additional eligible entities may ultimately include nonprofit organizations, institutions of higher education, healthcare systems, and other qualified domestic organizations once the full notice of funding opportunity is posted. Applicants are expected to submit applications electronically through Grants.gov no later than 11:59 p.m. Eastern Time on the application due date. The opportunity is currently in forecast status. HRSA lists an estimated posting date of May 15, 2026, with an estimated application due date of June 15, 2026. The archive date for the opportunity is July 15, 2026. At the time of this analysis, no letter of intent, concept paper, or pre-application requirement has been identified in the forecast notice. Similarly, the notice does not yet provide detailed application instructions, review criteria, required attachments, or evaluation scoring methodology. Those details are expected to become available once the official application package and full notice are released. Because the opportunity is forecasted rather than fully posted, applicants should monitor Grants.gov and HRSA announcements for additional guidance, required forms, and technical submission instructions. The listed program contact for the opportunity is Nordia Williams of the Health Resources and Services Administration. The contact phone number is 240-475-3310 and the listed email address is nwilliams1@hrsa.gov. Prospective applicants may use this contact information for questions related to eligibility, program intent, or future release details. The forecast notice does not indicate whether this funding opportunity recurs annually, and no recurring cycle language is provided. Therefore, the current opportunity should be treated as a single forecasted funding cycle until HRSA publishes additional information regarding future competitions or continuation opportunities.

Emphasize capacity to expand coordinated HHT care access, support clinician diagnosis strategies, and manage rare disease patient registry infrastructure.